Boston, MA 05/09/2014 (wallstreetpr) – Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s Acthar continues to focus on treatment of multiple indications. The recent studies proved that Acthar may be an alternate option for the treatment of systemic lupus erythematosus (SLE) patients.
Acthar
The U.S. Food and Drug Administration (FDA) already approved the medicines for 19 indications including the treatment of selected cases of SLE. Questcor is also pursuing the FDA approval for additional indications to address high unmet medical needs.
The clinical trial studies revealed that Acthar reduces the lupus disease activity significantly due to its efficiency and safety with no side effects. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) continues to evaluate the efficiency and safety on a large scale to consider Acthar as a treatment option for SLE.
SLE
SLE, an autoimmune disease, usually affects many organs of human beings including skin, joints, kidneys, brain, and other organs. There is no cure available to treat patients suffering from SLE; however, control measures can improve the survival rate. GlaxoSmithKline’s Benlysta considered as a standard treatment to reduce the intensity of the disease. But, modest efficacy and slow response create opportunity for drug makers to develop new medicines.
Even, research firms like Decision Resources also expects that the treatment market will grow with the advent of new medicines and anticipates that SLE therapy market will reach $4 billion by 2022. On such scenario, the market will give the opportunity for Questcor’s Acthar considering the positive outcome against SLE.
Final take
The rising prescriptions from rheumatologists’ on a variety of immunosuppressive diseases including SLE increase the sales of Acthar. The Company’s revenue increased significantly due to the extended use of Acthar in multiple indications. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) continues to identify and expand Acthar’s use in existing and new indications. In contrast, high costs may be a risk factor to serve a larger group of patients across geographies.
